MOTS-c

MOTS-c is a 16‑amino‑acid microprotein produced within mitochondria, the energy centers of cells. It is encoded by a short stretch of mitochondrial DNA (12S rRNA region) and acts as a mitokine — a signal that travels through the body to help tissues adapt to metabolic and oxidative stress MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases+1.

Research focuses on its role in stress resilience: preserving mitochondrial function, dampening excessive inflammation, and engaging built‑in antioxidant defenses. It is not a classic hormone but rather a stress‑response peptide that shifts cellular priorities toward repair and efficiency when energy demand is high or injury threatens MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases+1.

Current knowledge comes mostly from animal models of heart, lung, muscle, and metabolic disorders, plus human observational studies that link circulating MOTS‑c levels to conditions like obesity, diabetes, and cardiovascular stress MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases+3. There are no human interventional trials yet.

MOTS‑c works primarily by engaging two ancient cellular pathways: AMPK, a master energy sensor, and its downstream partner PGC‑1α, which controls mitochondrial quality and quantity. By activating AMPK, MOTS‑c signals cells to improve energy efficiency, burn fat, and resist oxidative damage — all without necessarily building more mitochondria MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner+1.

A second major arm is the Nrf2 pathway, a built‑in antioxidant program. When MOTS‑c activates Nrf2, cells produce enzymes that neutralize reactive oxygen species and survive challenges like low oxygen or toxins. This Nrf2‑dependency has been confirmed in lung, cartilage, and placental injury models, where protection is lost if Nrf2 is blocked Mitochondria-derived peptide MOTS-c alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice by activating Nrf2 pathway+2.

MOTS‑c also preserves mitochondrial quality control through mitophagy (the selective recycling of damaged mitochondria via Pink1/Parkin), suppresses the NLRP3 inflammasome to reduce inflammation, and, in certain tissues, limits ferroptosis (a form of iron‑dependent cell death) by upregulating SLC7A11 Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model+2.

These effects are tissue‑specific. For example, in skeletal muscle, MOTS‑c improves mitochondrial respiration without increasing mitochondrial content, a “qualitative” upgrade MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. In the heart, it can shrink infarct size by 73% when given around the time of reperfusion in experimental models Exogenous MOTS-c mitigates myocardial ischemia-reperfusion injury: experimental and in silico evidence from rat heart models.

The research literature documents several effect domains, though none are backed by randomized human trials.

Metabolic and mitochondrial health

• Improves skeletal muscle mitochondrial bioenergetics in a PGC‑1α/AMPK‑dependent manner, reducing ROS emission and oxidative protein damage MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.
• Reduces fasting glucose, CRP, and inflammatory cytokines in a diabetic rat model, suggesting anti‑diabetic potential Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model.
• Circulating MOTS‑c levels correlate with metabolic dysregulation: higher in obesity and acute coronary syndrome, lower in Hashimoto’s thyroiditis and some inflammatory states Reduced Circulating MOTS-c Levels in Hashimoto's Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysregulation: A Cross-Sectional Study+2.

Cardiac and vascular protection

• In rat heart ischemia‑reperfusion, exogenous MOTS‑c at 0.5 mg/kg reduced infarct size by 73% and preserved mitochondrial integrity Exogenous MOTS-c mitigates myocardial ischemia-reperfusion injury: experimental and in silico evidence from rat heart models+1.
• Suppressed cardiac fibrosis and inflammasome activation in diabetic and atrial fibrillation models Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model+2.
• Human observational studies link lower postoperative MOTS‑c to worse cardiac injury risk and higher levels to prognosis in acute coronary syndrome The Association Between Serum MOTS-c Levels and Myocardial Ischemia-Reperfusion Injury in Patients with Acute Myocardial Infarction: A Cross-Sectional Study+1.

Muscle and exercise‑mimetic effects

• Prevents dexamethasone‑induced muscle atrophy in human muscle cells, preserving myotube size and reducing atrophy markers Mitochondrial‐derived peptides <scp>MOTS</scp> ‐c and humanin attenuate dexamethasone‐induced atrophy in human skeletal muscle cells.
• Partially preserved quadriceps mass and reduced atrogin‑1/MuRF1 in a mouse cachexia model MOTS-c partially protects against skeletal muscle deterioration in C26 cachexia.

Tissue protection and anti‑inflammatory actions

• Reduces lung injury, inflammation, and cell death in hyperoxia, radiation, and COPD models; Nrf2‑dependence confirmed Mitochondria-derived peptide MOTS-c alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice by activating Nrf2 pathway+2.
• Slowed cartilage degeneration and suppressed pyroptosis in osteoarthritis models MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism.
• Attenuated acetaminophen‑induced liver injury via MAPK pathway suppression MOTS-c Protects Against Acetaminophen-induced Liver Injury through the MAPK Signaling Pathway.
• In sepsis‑associated brain injury, improved survival and stabilized the blood‑brain barrier A mitochondrial-derived peptide MOTS-c contributes to the protective effect against brain injury associated with LPS-induced sepsis by strengthening the blood-brain barrier's ultrastructure.

Reproductive and endocrine

• Improved spermatogenesis in oligoasthenozoospermia models by reducing ferroptosis Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis.
• Primed adrenal cortex metabolism without directly raising steroidogenesis Mitochondrial open reading frame of the 12S rRNA type-c (MOTS-c) primes adrenal cortex metabolism without directly driving steroidogenesis.

No standardized human protocol exists; all current dosing patterns are extrapolated from animal efficacy studies and practitioner experience.

Preclinical dosing anchors

Animal studies show activity from 0.5 mg/kg (optimal in a rat heart ischemia‑reperfusion model) to 20 mg/kg (LPS‑sepsis brain injury) given intraperitoneally Exogenous MOTS-c mitigates myocardial ischemia-reperfusion injury: experimental and in silico evidence from rat heart models+1. Common disease‑model doses are 5 mg/kg daily for 2 weeks (lung/placental injury) or 15 mg/kg twice daily for cachexia Mitochondria-derived peptide MOTS-c alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice by activating Nrf2 pathway+1.

Typical research protocols

Community‑derived protocols for human investigation most often use subcutaneous injection:

• General metabolic support: 5–10 mg once daily, 5 days on/2 days off, for 2–4 weeks.
• Exercise recovery/recomposition: 10–15 mg once daily, often pre‑workout, for 10–14 days up to 4 weeks.
• Body‑weight‑adjusted: 0.07–0.15 mg/kg/day, which for a 70 kg subject equals approximately 5–10.5 mg/day.

These doses are well below most animal models on a mg/kg basis. Fasted morning administration is preferred to align with ampk‑driven metabolic rhythms Mitochondrial‐derived peptides <scp>MOTS</scp> ‐c and humanin attenuate dexamethasone‐induced atrophy in human skeletal muscle cells+1.

Timing and cycling

Benefits typically appear within 3–7 days for subjective energy and exercise tolerance and peak around days 10–21. Short cycles (2–4 weeks) are the norm because chronic continuous human data are absent MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases+1.

MOTS‑c is handled like other lyophilized research peptides. Use bacteriostatic water for multi‑dose vials or sterile water for short‑term use. Add diluent slowly down the vial wall and swirl gently; avoid shaking, which can degrade the peptide MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases+1.

Concentration choice depends on the target dose. To keep injection volumes manageable for doses in the 5–15 mg range, many researchers prefer a final concentration of 5–10 mg/mL Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. An interactive reconstitution calculator on this page automates the math; refer to it for exact volumes.

Storage

• Lyophilized powder: store at -20°C for long‑term; 2–8°C for short‑term.
• Reconstituted solution: keep refrigerated (2–8°C), protect from light, and use within 14–28 days if bacteriostatic water was used, or 7–14 days with sterile water. Freezing aliquots can extend this to 1–3 months.
• Avoid repeated freeze‑thaw cycles and discard if cloudiness or particles appear Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Formal human drug interaction studies are absent. Interactions are therefore inferred from mechanism and preclinical data.

Potential synergistic interactions

• Glucose‑lowering agents (metformin, GLP‑1 agonists, insulin): additive hypoglycemia risk, as MOTS‑c lowers fasting glucose in diabetic models Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model+1. Monitor blood glucose closely.
• Nrf2 activators (sulforaphane, curcumin): may potentiate antioxidant effects, since MOTS‑c’s lung and cartilage protection is Nrf2‑dependent Mitochondria-derived peptide MOTS-c alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice by activating Nrf2 pathway+1.
• Other mitochondrial peptides (humanin, SS‑31): likely complementary; humanin and MOTS‑c both reduced atrial fibrosis in models Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Stacking is common experimentally.

Theoretical concerns

• MAPK‑targeted drugs: MOTS‑c suppresses ERK/JNK/p38 in liver injury models, so biomarker interpretation may be confounded MOTS-c Protects Against Acetaminophen-induced Liver Injury through the MAPK Signaling Pathway.
• Immunomodulators: MOTS‑c reduces NLRP3 inflammasome markers, so additive anti‑inflammatory effects are possible Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model.
• Corticosteroids: MOTS‑c counteracted dexamethasone‑induced atrophy in muscle cells, suggesting a protective interaction Mitochondrial‐derived peptides <scp>MOTS</scp> ‐c and humanin attenuate dexamethasone‐induced atrophy in human skeletal muscle cells.

Supplements

Berberine, NR/NMN, and CoQ10 share AMPK/mitochondrial pathways; start one at a time to gauge response. Creatine and fish oil are considered compatible MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner+1.

Cycling is used because MOTS‑c acts as a stress‑response signal, not a chronic hormone replacement. Preclinical studies show effects within days, and circulating endogenous MOTS‑c fluctuates with physiological state, suggesting intermittent use is biologically plausible MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases+1.

Typical cycles

• 2–4 weeks on, 2–4 weeks off is the most common pattern for metabolic or exercise support.
• 5 days on, 2 days off (weekly structure) extended to 2–6 weeks is also used.
• Conservative first‑exposure protocol: 5 mg/day, 5 on/2 off, for 2 weeks, then reassess.

Rationale

Short blocks align with animal models (most 2‑week protocols) and the observation that benefits plateau after 2–3 weeks. Because MOTS‑c upregulates AMPK and Nrf2, continuous stimulation could theoretically desensitize pathways, though no human study confirms this MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner+1. Additionally, circulating MOTS‑c does not change in a simple “replace‑deficiency” pattern — levels may be high in obesity yet low in autoimmunity — so indefinite use lacks a clear biomarker target Reduced Circulating MOTS-c Levels in Hashimoto's Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysregulation: A Cross-Sectional Study+1.

A break is warranted if initial improvements fade after 10–21 days, or if over‑stimulation symptoms (restlessness, appetite suppression, sleep disruption) appear Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

MOTS‑c is frequently stacked experimentally with other peptides to target complementary pathways.

Common stacks

• Humanin: Both are mitochondrial‑derived peptides; in models, humanin and MOTS‑c jointly reduced atrial fibrosis and improved mitochondrial dynamics Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction.
• SS‑31 (Elamipretide): Targets inner mitochondrial membrane stability; combined with MOTS‑c’s AMPK‑driven efficiency, it’s a popular experimental stack for mitochondrial health Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
• BPC‑157: Different mechanisms — BPC‑157 promotes angiogenesis and wound healing, while MOTS‑c handles metabolic stress. Often used together in recovery protocols Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
• Growth hormone secretagogues (CJC‑1295/Ipamorelin, Tesamorelin): MOTS‑c may offset the insulin resistance sometimes seen with GH peptides via its glucose‑lowering effects Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model+1.
• AOD‑9604: Both are used for body composition research; no direct interaction data, but AOD‑9604’s lipolytic profile and MOTS‑c’s mitochondrial support are seen as complementary Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

When introducing a stack, researchers typically add MOTS‑c as the single new variable for 1–2 weeks to assess tolerance before combining Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

MOTS‑c is an unapproved, investigational peptide. No FDA, EMA, or other major regulatory body has authorized it as a therapeutic product. It is described in the 2026 sports‑medicine literature as an “unapproved peptide” with scarce human safety data Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

In anti‑doping, analytical methods are being developed to detect MOTS‑c, reflecting concern about its performance‑enhancing potential. Athletes should treat it as high‑risk for sanctions, even if a specific WADA class is not yet cited in this corpus Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025+1.

There is no Controlled Substances Act scheduling, but marketing it with human treatment claims would violate FDA regulations Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Human safety data are very limited. No controlled trials have established adverse event rates, and the side‑effect profile is inferred from animal studies and practitioner observations MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases+2.

Reported and theoretical effects

• Common: injection‑site reactions (pain, redness) are expected with any subcutaneous peptide. Subjective effects like mild fatigue, appetite suppression, or lightheadedness have been noted, consistent with AMPK activation Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
• Hypoglycemia risk: Because MOTS‑c lowers glucose in animal models, lean individuals, those fasting, or those on glucose‑lowering drugs may experience low blood sugar Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model+1.
• Over‑stimulation: Restlessness, worsened sleep, or exercise‑like soreness at cycle start, possibly from excessive metabolic activation Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
• Uncertain long‑term effects: No chronic toxicity data exist. Given its influence on cell death pathways (ferroptosis, pyroptosis, oxeiptosis) and mitochondrial dynamics, cancer safety is unresolved MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases+1.
• Reproductive caution: Placental and adrenal effects in animal models suggest pregnancy and fertility contexts should be avoided outside specialist supervision Mitochondrial open reading frame of the 12S rRNA type-c (MOTS-c) primes adrenal cortex metabolism without directly driving steroidogenesis+1.

Contraindications

• Active severe hypoglycemia or inability to monitor glucose.
• Concurrent use with insulin/insulin secretagogues without medical oversight.
• Pregnancy, breastfeeding, or active cancer (precautionary).
• Unstable cardiovascular disease or recent heart attack.

Monitoring fasting glucose, liver enzymes, and inflammatory markers (CRP) during experimental use is advised Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model+1.